Description: TemCad is a pharmaceutical product available in capsule form, with each capsule containing 250 mg of Temozolomide as the active ingredient. Temozolomide is an oral alkylating agent primarily used in the treatment of certain types of brain tumors, including glioblastoma multiforme and anaplastic astrocytoma.

Composition: Each TemCad capsule comprises 250 mg of Temozolomide, and the formulation may include various excipients to maintain stability and proper dosage form.

Uses: TemCad is prescribed for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy, as well as for the treatment of refractory anaplastic astrocytoma in adult patients. Temozolomide interferes with the growth of cancer cells by disrupting their DNA, thereby inhibiting their ability to divide and multiply.

Usage and Dosage: The dosage and administration of TemCad are determined by the treating healthcare professional based on the patient’s specific medical condition, overall health, and other relevant factors. Patients are advised to strictly adhere to the prescribed dosage and schedule, and the capsules are typically taken orally with water.

Storage Conditions: TemCad capsules should be stored in accordance with the manufacturer’s recommendations. Typically, they are stored in a cool, dry place, away from direct sunlight, and at a controlled room temperature. It is crucial to keep the medication out of the reach of children.

Mechanism of Action: Temozolomide, the active ingredient in TemCad, is an alkylating agent that converts to the active compound, MTIC (methyl-triazeno imidazole carboxamide), in the body. MTIC methylates DNA at the O6 and N7 positions of guanine, leading to DNA strand breaks and inhibiting DNA synthesis. This mechanism disrupts the growth and division of cancer cells, contributing to the antitumor effects.

Contraindications: TemCad is contraindicated in individuals with a known hypersensitivity to Temozolomide or any components of the formulation. Patients should inform healthcare providers of any existing allergies or adverse reactions to medications.

Interactions: Temozolomide may interact with other medications, and healthcare professionals should be aware of any concurrent drug therapies. Specific drugs affecting liver enzyme systems or those causing myelosuppression may interact with Temozolomide, potentially impacting its efficacy or increasing the risk of adverse effects.

Adverse Reactions: Common adverse reactions associated with TemCad may include myelosuppression (decreased blood cell counts), nausea, vomiting, fatigue, and headache. Patients should promptly report any unusual or severe side effects to their healthcare provider.

Patients are advised to consult with their healthcare provider for personalized information regarding the use of TemCad, as individual responses to medication can vary. Regular communication with the healthcare team is important for optimal management and monitoring during brain tumor treatment.